Dr Paul Davis BSc(Hons), PhD, FICA, Senior Research Fellow
- Senior Research Fellow at the GMRI
- Chief Executive and Director of Research at Trinity Bioactives
- Scientific Leader at QOL Health Diagnostics
Honours and awards
- Australian and New Zealand Head and Neck Cancer Society Research Foundation Prize, 2014
- Research provider to a project on development of natural medicines in Vietnam (SaPa region), 2007
- First prize in SEED Award from United Nations, 2007
- Formerly a Fulbright Fellow
- Member of International College of Angiology, New York
- Member of New York Academy of Sciences, New York
- Member of Wellington Health and Biomedical Research Society
- Member of Plastic Reconstructive Surgery Research Foundation
- Member of Royal Society of New Zealand
- Member of NZ Bio
- Member of Oncology Society of Japan
Dr Davis has been involved in biomedical research continuously since 1969. He graduated from the University of Otago and was awarded a PhD by Massey University. He received a Fulbright Scholarship to undertake post-doctoral research at the University of Texas at Austin, in Dr Lester Reed’s group.
On returning to New Zealand in 1978 Dr Davis led a group at the Malaghan Institute of Medical Research studying extracellular matrix in various diseases, particularly vascular conditions. In 1992 he transferred to the University of Otago and became the leader of the Renal Research Group, which had active collaborations with several other laboratories. His interests expanded further to include angiogenesis and the biological activities of compounds and extracts, which led to the establishment of the Bioactivity Investigation Group (BIG).
In 2008 Trinity Bioactives Ltd purchased BIG from the University of Otago and Dr Davis became Chief Executive and Director of Research of the company. He retired from the University of Otago in December 2012 although he continued to hold an honorary senior research fellow position until December 2015.
Dr Davis is a founding member of the Boards of the Gillies McIndoe Foundation and the Gillies McIndoe Research Institute. He was acting Chief Scientific Officer of the GMRI during the establishment of its facilities in Newtown.